JP2008532014A - 生物試料を分類するための組成物及び方法 - Google Patents
生物試料を分類するための組成物及び方法 Download PDFInfo
- Publication number
- JP2008532014A JP2008532014A JP2007557159A JP2007557159A JP2008532014A JP 2008532014 A JP2008532014 A JP 2008532014A JP 2007557159 A JP2007557159 A JP 2007557159A JP 2007557159 A JP2007557159 A JP 2007557159A JP 2008532014 A JP2008532014 A JP 2008532014A
- Authority
- JP
- Japan
- Prior art keywords
- binding activity
- epitope
- epitopes
- class
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 90
- 239000012472 biological sample Substances 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 89
- 230000027455 binding Effects 0.000 claims description 254
- 239000000523 sample Substances 0.000 claims description 177
- 238000002493 microarray Methods 0.000 claims description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 238000001514 detection method Methods 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 description 114
- 201000011510 cancer Diseases 0.000 description 95
- 201000010099 disease Diseases 0.000 description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
- 206010006187 Breast cancer Diseases 0.000 description 43
- 208000026310 Breast neoplasm Diseases 0.000 description 43
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 43
- 201000005202 lung cancer Diseases 0.000 description 43
- 208000020816 lung neoplasm Diseases 0.000 description 43
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 40
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 36
- 206010041067 Small cell lung cancer Diseases 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 230000000875 corresponding effect Effects 0.000 description 31
- 239000013598 vector Substances 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 25
- 238000009739 binding Methods 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000003909 pattern recognition Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000002790 cross-validation Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 238000012549 training Methods 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 230000002860 competitive effect Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012706 support-vector machine Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 2
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 2
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 2
- 102100024276 Transcription factor SOX-3 Human genes 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010053101 ELAV Proteins Proteins 0.000 description 1
- 102000016662 ELAV Proteins Human genes 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102100025654 Endosome-associated-trafficking regulator 1 Human genes 0.000 description 1
- 101001056455 Homo sapiens Endosome-associated-trafficking regulator 1 Proteins 0.000 description 1
- 101000603223 Homo sapiens Nischarin Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000723902 Homo sapiens Zinc finger protein 292 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 102100038995 Nischarin Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100028431 Zinc finger protein 292 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65685905P | 2005-02-24 | 2005-02-24 | |
| PCT/US2006/006431 WO2006091734A2 (en) | 2005-02-24 | 2006-02-24 | Compositions and methods for classifying biological samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008532014A true JP2008532014A (ja) | 2008-08-14 |
| JP2008532014A5 JP2008532014A5 (enExample) | 2009-04-16 |
Family
ID=36928007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557159A Withdrawn JP2008532014A (ja) | 2005-02-24 | 2006-02-24 | 生物試料を分類するための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090075832A1 (enExample) |
| EP (1) | EP1859266A4 (enExample) |
| JP (1) | JP2008532014A (enExample) |
| KR (1) | KR20080003321A (enExample) |
| CN (1) | CN101160524A (enExample) |
| AU (1) | AU2006216683A1 (enExample) |
| CA (1) | CA2598889A1 (enExample) |
| IL (1) | IL185458A0 (enExample) |
| MX (1) | MX2007010349A (enExample) |
| RU (1) | RU2007135030A (enExample) |
| WO (1) | WO2006091734A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013505296A (ja) * | 2009-09-22 | 2013-02-14 | ヤンセン ファーマシューティカ エヌ．ベー． | 多発性骨髄腫細胞からの抗原ペプチドの同定 |
| WO2013031757A1 (ja) * | 2011-08-29 | 2013-03-07 | 東レ株式会社 | 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842480B2 (en) | 2001-05-18 | 2010-11-30 | Mayo Foundation For Medical Education And Research | Chimeric antigen-specific t cell-activating polypeptides |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| JP5564249B2 (ja) * | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2201024A1 (en) | 2007-08-28 | 2010-06-30 | Ramot At Tel Aviv University | Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site |
| TWI466680B (zh) * | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| GB0823366D0 (en) * | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
| KR101067815B1 (ko) * | 2009-02-05 | 2011-09-27 | 서울대학교산학협력단 | 제1형 당뇨병의 신규한 진단 마커 |
| EP3444613B1 (en) | 2009-08-14 | 2021-05-19 | The Regents of The University of California | Methods of diagnosing and treating autism |
| TWI485245B (zh) * | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗 |
| JP6294221B2 (ja) | 2011-03-31 | 2018-03-14 | アー・デー・ツェー・セラピューティクス・エス・アー | 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント |
| EP2745115B1 (de) * | 2011-08-19 | 2016-05-18 | Protagen AG | Neues verfahren zur diagnostik von hochaffinen bindern und markersequenzen |
| TR201908872T4 (tr) | 2012-01-09 | 2019-07-22 | Adc Therapeutics Sa | Üçlü negatif meme kanserini tedavi etmek için ajanlar. |
| US20130183242A1 (en) * | 2012-01-18 | 2013-07-18 | University Of Connecticut | Methods for identifying tumor-specific polypeptides |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| WO2015172843A1 (en) * | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
| EP3145516A4 (en) * | 2014-05-20 | 2018-06-13 | Kiromic, LLC | Methods and compositions for treating malignancies with dendritic cells |
| AU2016209247B2 (en) | 2015-01-21 | 2021-02-25 | Inhibrx Biosciences, Inc. | Non-immunogenic single domain antibodies |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| EP4300101A3 (en) | 2015-06-26 | 2024-03-20 | The Regents Of The University Of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
| EP3322734B1 (en) | 2015-07-16 | 2020-09-09 | Inhibrx, Inc. | Multivalent and multispecific dr5-binding fusion proteins |
| HK1258386A1 (zh) | 2015-10-05 | 2019-11-08 | Immatics Biotechnologies Gmbh | 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物 |
| EP3193173A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Serological autoantibodies as biomarker for colorectal cancer |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| ES2946584T3 (es) * | 2017-01-27 | 2023-07-21 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| CN108948184B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别衍生自prame抗原短肽的t细胞受体 |
| CN109400697B (zh) * | 2017-08-17 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别prame抗原短肽的tcr及其相关组合物 |
| EP3756680A1 (en) * | 2019-06-26 | 2020-12-30 | Universitat de Lleida | Intermediate filament-derived peptides and their uses |
| EP3999525A4 (en) * | 2019-07-15 | 2023-08-09 | Geisinger Health System | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST CANCER WITH A NOVEL CAPER ALPHA MLL1 COMPLEX |
| CN110922492B (zh) * | 2019-12-18 | 2022-02-15 | 重庆医科大学 | 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法 |
| CN111337678B (zh) * | 2020-02-21 | 2023-06-06 | 杭州凯保罗生物科技有限公司 | 与肿瘤免疫治疗效果相关的生物标志物及其应用 |
| CN116773798A (zh) * | 2023-06-16 | 2023-09-19 | 北京三品医疗科技有限公司 | 多肽的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| CA2432639A1 (en) * | 2000-11-16 | 2002-05-23 | Cemines, Llc | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
| AU2002302410A1 (en) * | 2001-03-10 | 2002-09-24 | Affina Immuntechnik Gmbh | Method for identifying immune reactive epitopes on proteins |
| JP4594588B2 (ja) * | 2001-04-10 | 2010-12-08 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ | 抗体特異的プロファイルの治療的および診断的使用方法 |
| AU2002347778A1 (en) * | 2001-09-28 | 2003-05-26 | Incyte Genomics, Inc. | Enzymes |
| WO2004058972A1 (de) * | 2002-12-23 | 2004-07-15 | Thiesen Hans-Juergen | Human-autoantigene und deren verwendung |
| JP2006524035A (ja) * | 2002-12-26 | 2006-10-26 | シーマインズ リミテッド ライアビリティ カンパニー | 癌の診断、予後診断および治療のための方法および組成物 |
-
2006
- 2006-02-24 JP JP2007557159A patent/JP2008532014A/ja not_active Withdrawn
- 2006-02-24 WO PCT/US2006/006431 patent/WO2006091734A2/en not_active Ceased
- 2006-02-24 US US11/817,010 patent/US20090075832A1/en not_active Abandoned
- 2006-02-24 CN CNA2006800126573A patent/CN101160524A/zh active Pending
- 2006-02-24 RU RU2007135030/15A patent/RU2007135030A/ru not_active Application Discontinuation
- 2006-02-24 KR KR1020077021910A patent/KR20080003321A/ko not_active Withdrawn
- 2006-02-24 MX MX2007010349A patent/MX2007010349A/es not_active Application Discontinuation
- 2006-02-24 CA CA002598889A patent/CA2598889A1/en not_active Abandoned
- 2006-02-24 AU AU2006216683A patent/AU2006216683A1/en not_active Abandoned
- 2006-02-24 EP EP06735911A patent/EP1859266A4/en not_active Withdrawn
-
2007
- 2007-08-22 IL IL185458A patent/IL185458A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013505296A (ja) * | 2009-09-22 | 2013-02-14 | ヤンセン ファーマシューティカ エヌ．ベー． | 多発性骨髄腫細胞からの抗原ペプチドの同定 |
| WO2013031757A1 (ja) * | 2011-08-29 | 2013-03-07 | 東レ株式会社 | 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090075832A1 (en) | 2009-03-19 |
| KR20080003321A (ko) | 2008-01-07 |
| EP1859266A2 (en) | 2007-11-28 |
| WO2006091734A2 (en) | 2006-08-31 |
| CA2598889A1 (en) | 2006-08-31 |
| WO2006091734A3 (en) | 2007-02-08 |
| CN101160524A (zh) | 2008-04-09 |
| AU2006216683A1 (en) | 2006-08-31 |
| IL185458A0 (en) | 2008-01-06 |
| EP1859266A4 (en) | 2010-07-28 |
| RU2007135030A (ru) | 2009-03-27 |
| MX2007010349A (es) | 2008-04-09 |
| WO2006091734A9 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532014A (ja) | 生物試料を分類するための組成物及び方法 | |
| US11067582B2 (en) | Peptide array quality control | |
| US20120053080A1 (en) | Protein markers identification for gastric cancer diagnosis | |
| US20080081339A1 (en) | Tumor associated markers in the diagnosis of prostate cancer | |
| JP6774925B2 (ja) | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット | |
| JP2017067792A (ja) | 腺癌の検出のための蛋白質シグネチャー／マーカー | |
| JP2006509186A (ja) | 前立腺癌バイオマーカー | |
| JP2016507748A (ja) | 卵巣癌の早期発見のための自己抗体サイン | |
| AU2014345484A1 (en) | Method, array and use thereof for determining pancreatic cancer | |
| US20190056402A1 (en) | Organ specific diagnostic panels and methods for identification of organ specific panel proteins | |
| JP2013529773A (ja) | 方法、アレイ、およびこれらの使用 | |
| JP6674889B2 (ja) | 前立腺がんに対するバイオマーカー検出における使用のための方法とアレイ | |
| JP2019526810A (ja) | バイオマーカーサインおよびそれらの使用 | |
| KR102839146B1 (ko) | 류마티스 관절염 자가항체 레퍼토리의 프로파일링 및 그의 펩타이드 분류자 | |
| Rodenburg et al. | Identification of breast cancer biomarkers in transgenic mouse models: A proteomics approach | |
| WO2026050338A1 (en) | Protein-based biomarkers and related aspects for differentiating lyme disease from other non-lyme febrile diseases | |
| HK40058647B (zh) | 监定、评估、预防以及治疗肺疾病的方法及试剂盒 | |
| WO2025171422A1 (en) | Method for diagnosing pancreatic ductal adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090224 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110331 |